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Abstract
Objective: Autism is a neurodevelopmental disorder characterized by difficulty in verbal 
and non-verbal communication, impaired social interaction, and restricted and repetitive 
behavior. It has been recently introduced as a multigenic disorder with significant epi-
genetic effects on its pathology. Recently, epigenetic silencing of retinoic acid receptor-
related orphan receptor alpha (RORα) gene (which has an essential role in neural tissue 
development) was shown to have occurred in autistic children due to methylation of its 
promoter region. This may thus explain a significant part of the molecular pathogenesis 
of autism. Therefore, we aimed to confirm this finding by implementing a case-control 
(experimental) study in the population of Isfahan.
Materials and Methods: The methylation status of a 136 bp sequence of a GpG island 
(encompassing 13 CpG sites)  in the RORA promoter region (positions -200 to -64) as an 
experimental study was examined in the lymphocyte cells of 30 autistic children after so-
dium bisulfite treatment using the melting curve analysis-methylation (MCA-Meth) assay 
compared with normal children. Also, quantitative reverse transcriptase-polymerase chain 
reaction (qRT-PCR) analysis was used to estimate the level of mRNA transcripts and to 
evaluate MCA-Meth analysis results.
Results: This study revealed no methylation in the examined promoter regions in both 
autistic and normal children, with the melting curve of all studied samples being compa-
rable to that of the non-methylated control. The results of MCA-Meth analysis were also 
consistent with qRT-PCR results. We therefore observed no significant difference in the 
levels of RORα transcripts in the blood lymphocytes between autistic and healthy children. 
Conclusion: The methylation of the RORA promoter region may not be considered as a 
common epigenetic risk factor for autism in all populations. Hence, the molecular patho-
genesis of autism remains unclear in the population investigated.             
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Introduction
Autism is a highly heterogeneous disease, to the ex-
tent that there are no two autistic children with 100% 
identity in features. Nevertheless, autism is charac-
terized by four common features: impaired social 
communication and interaction, different language 
impairments, repetitive and stereotyped behaviors, 
often with restricted interests (1, 2). Autism is the 
most devastating form of autism spectrum disorders 
(ASD) and the diagnostic criteria require that symp-
toms become apparent in early childhood, typically 
before age three. Autism has experienced an incred-
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ible increase in prevalence in the past three decades 
(3). Although genetic studies have suggested that 
schizophrenia and autism are highly heritable psychi-
atric disorders (4), they were, however, not successful 
in explaining the pathogenesis of autism.
The role of epigenetic factors in the pathogenesis 
of autism was recently proposed and confirmed (5). 
For example, certain polymorphisms of the MeCP2 
gene, a global epigenetic regulator, were associated 
with an increased risk of autism (6). Methylation of 
the oxytocin receptor promoter have also been shown 
to be associated with autism (7). More recently, DNA 
methylation of 485,000 CpG sites in a pilot study of 
postmortem brain tissue (from three brain regions 
including dorsolateral prefrontal cortex, temporal 
cortex and cerebellum) from autistic cases were ex-
amined. This study revealed suggestive evidence for 
commonly altered methylation sites in ASD (8).
The retinoic acid receptor-related orphan receptor 
alpha (RORα) also known as nuclear receptor sub-
family 1, group F, member 1 (NR1F1) gene located on 
chromosome 15 (15q22.2), spans 741 kb and contains 
11 exons. RORA encodes the transcription activator 
RORα, also known as NR1F1 with 556 aminoacids 
in length. RORα is a subfamily of the steroid hor-
mone nuclear receptor superfamily and is involved in 
transcriptional regulation of many genes. Among its 
many known functions are regulation of the circadian 
clock, neuroprotection, survival and differentiation 
of Purkinje cells, and cerebellar development. All of 
these associated functions implicate RORA as a po-
tential autism susceptibility gene with a significant 
role in autism pathogenesis (9). RORα is expressed 
in multiple tissues including testis, adipose tissue, 
kidney and liver. A high level of RORα expression 
has been observed in nerural tissues especially in the 
cerebellum and thalamus (10). The role of RORα in 
the process of brain development has not been widely 
studied beyond the cerebellum (11). However, for the 
first time, in 2010, Nguyen et al. (12) completed large-
scale DNA methylation profiling of lymphoblastoid 
cell lines derived from monozygotic twins discordant 
for autism and their nonautistic siblings. They ob-
served decreased expression of RORα in the autistic 
brain and suggested RORA to be a novel candidate 
gene for autism pathogenesis. Moreover, RORα-
deficient mice showed various abnormalities includ-
ing long thin bones (suggesting a role of RORα in 
bone formation), severe cerebellar atrophy and ataxia 
(13, 14). It seems a possible link between RORα and 
pathogenesis of Spinocerebellar ataxia type 1 (SCA1) 
is via decreasing the number of cerebellar Purkinje 
cells (15).
Given the role of RORA in the pathogenesis of 
nervous system disorders and its epigenetic impact 
on the incidence of autism, we aimed to investigate 
the methylation of the RORA promoter region in au-
tistic cases. Moreover, considering the fact that other 
factors than methylation can affect gene expression, 
we also estimated the expression of RORA in autistic 




This pilot experimental study was carried out after 
the approval of the Ethics Committee of the Behav-
ioral Sciences Research Center of Isfahan University 
of Medical Sciences and Molecular and Cellular Re-
search Center of Shahr-e Kord University of Medical 
Sciences.
This study was performed on 30 autistic chil-
dren (1 concordant monozygotic twin, 1 discord-
ant monozygotic twin, two concordant dizygotic 
twins and 22 autistic individuals) who were under 
the care of Isfahan Society of Autistic Children. 
A relevant specialist had confirmed that they were 
autistic children. In the studied population, 24 cas-
es were male and 6 cases were female. However, 
a total number of 10 normal siblings of the autistic 
cases (7 males and 3 females) were considered to 
be in-family control samples and 15 normal chil-
dren from the urban regions of Isfahan were stud-
ied as population control samples after confirming 
their mental and physical health. All the studied 
cases were below 12 years of age.
Peripheral blood sample was collected from all 
cases. The methylation of a 136 bp fragment of 
a CpG island in RORA promoter region (includ-
ing 13 CpG sites) was examined by melting curve 
analysis-methylation assay (MCA-Meth).
Isolation and bisulfite treatment of genomic 
DNA
Genomic DNA was isolated from lymphoblas-
toid cell lines (LCLs) using the QIAamp DNA 
Blood Mini-kit (Qiagen, Germany) and then un-
derwent bisulfite treatment for methylation analy-
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ses. Two micrograms of genomic DNA was treated 
with sodium bisulfite using the Epitect Bisulfite 
Kit (Qiagen, Germany) according to the manufac-
turer’s instructions.
After bisulfite treatment, DNA was amplified using 
specific primers that amplified 136 bp (-64 to -200) of 
a CpG island in the promoter region of RORA. This 
primer set did not discriminate between methylated 
and unmethylated sequences. The primers and PCR 
conditions were specific for bisulfite-treated DNA, 
and did not amplify untreated DNA. For controls, the 
EpiTect Control DNA and Control DNA Set (Qiagen, 





were designed for the region of interest using the 
Methprime (16) and Oligicalc online tools.
All of the methylation analysis PCRs were per-
formed using the Maxima SYBR Green/ROX Q-PCR 
Mastermix Kit (Thermoscientific) in a final volume of 
20 μL, containing 1 μL bisulfite-treated DNA and a 
final concentration of 0.4 μmol/L for the forward and 
reverse primers. Reactions were incubated in a Ste-
pOne™ quantitative real-time PCR detection System 
(Applied Biosystems, USA) at 95˚C for 8 minutes, 
then 40 cycles of 95˚C for 50 seconds, 55˚C for 45 
seconds and 72˚C for 45 seconds. Methylation was 
determined by the melting curve analysis of the PCR 
product at the end of the amplification cycle. The 
temperature was then ramped from 60 to 95˚C  with 
increments of 0.3˚C at each step, waiting 15 seconds 
on the first step, then 5 seconds for each step thereaf-
ter. The derivative of fluorescence over temperature 
(dF/dT) was determined for each PCR product using 
the StepOnetm Software v2.2 (Applied Biosystems, 
USA). The dF/dT curves of the samples were com-
pared with those of the unmethylated and methylated 
controls. A sample was considered methylated when 
there was a shift in its dF/dT curve away from that of 
the unmethylated control.
RNA isolation and real-time polymerase chain 
reaction
The qRT-PCR analysis of RORA was performed 
to examine the correlation between the expression 
of the transcript and methylation status as predicted 
by MCA-Meth analysis. Total RNA was isolated us-
ing TRIzol reagents (Invitrogen, USA) following the 
manufacturer’s protocol. RNA was then reverse tran-
scribed using RevertAid First Strand cDNA Synthesis 
Kit (Thermoscientific, USA) with oligo dT primers. 
The qRT-PCR was performed using SYBRGreen 
PCR Master mix with ROX (Fermentase, USA) in a 
final volume of 10 μL, containing 1 μL of cDNA and 





were previously shown to successfully amplify 
RORA transcripts in skeletal muscle cells (17). Trip-
licate reactions were incubated in the StepOne™ 
quantitative real-time PCR detection system (Applied 
Biosystems, USA) at 95˚C for 10 minutes, then for 
40 cycles of 95˚C for 15 seconds, 60˚C for 60 secf-
onds and 72˚C for 30 seconds. The gene of interest 
was then normalized against the reference gene glyc-
eraldehyde-3-phosphate dehydrogenase (GAPDH). 
The relative expression of the target gene was calcu-
lated according to the 2-ΔΔCt method as previously de-
scribed (18). The PCR products were electrophoresed 
on 1.5% (w/v) agarose gels and stained with ethidium 
bromide to confirm expected product sizes.
Statistical analysis
Unpaired t test was used to statistically compare 
the mRNA expression level of RORA. A P value 
below 0.05 was considered significant.
Ethical considerations
All patients’ parants filled out the consent form 
to participate in this study according to the proto-
col of the Ethical Review Board of the Behavioral 
Sciences Research Center of Isfahan University of 
Medical Sciences.
Results
No methylation was observed in all studied CpG 
islands since the melting curve of all studied samples 
were comparable to that of the non-methylated control.
The melting curve peak of the negative (com-
pletely non-methylated) and positive (completely 
methylated) controls was at 70.9˚C and 75.55˚C 
respectively (Figs.1, 2), showing a temperature 
range of 5˚C. The melting temperature (Tm) of 
the PCR products of all studied samples (includ-
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ing autistic cases, their normal siblings, and nor-
mal population controls) was 70.9˚C (Fig.3). This 
implies no methylation of any CpG site located in 
the promoter region of RORA.
The results of the qRT-PCR assay (Fig.4) in-
dicated no significant difference in the levels of 
RORA transcripts in the blood lymphocytes be-
tween autistic and control samples. This finding 
was consistent with the results of the MCA-Meth 
analysis. 
Fig.1: The melting curve of the non-methylated control.
Fig.2: The melting curve of the methylated control.
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Fig.3: Sample melting curves show conformity with the non-
methylated controls.
Fig.4: The comparison of RORA expression between controls 
and autistic samples (all data were normalized with GAPDH and 
compared with the control group expression.
      
Discussion
This study applied the MCA-Meth assay on the 
lymphocyte cells of 30 autistic children in order 
to confirm the increased methylation of the pro-
moter region of RORA gene and the consequent 
mRNA expression in autism pathogenesis in the 
Isfahan population. MCA-Meth protocol can de-
tect the global methylation of a PCR-amplified re-
gion based on the difference between PCR melt 
curves and corresponding positive and negative 
control melt curves. Following bisulfate treatment, 
a methylated sequence of DNA will retain a higher 
GC/AT ratio which in turn will melt at a higher 
temperature compared with a non-methylated se-
quence (19).
The melt curve of a sample will be considered 
to be positive for methylation if it shifts towards 
the positive control curve. MCA-Meth have some 
advantages over other DNA methylation screen-
ing methods specifically methylation-specific 
PCR (MSP) which include simplicity and no need 
for gel documentation, needing a little amount of 
genomic DNA (6-9 nanograms) compared with 
MSP (10-20 nanograms) (20), determination of 
the methylation quantity (in almost all CpG sites) 
and quality (methylated, non-methylated and 
semi-methylated conditions) in the considered se-
quence (in contrast with MSP), and the possibility 
of comparing it with bisulfate sequencing protocol 
in terms of specificity and sensitivity (21, 22).
RORA undertakes different tasks during the 
growth and development of human tissues includ-
ing the nervous tissue, and similar to other genes it 
can be suppressed through the methylation of CpG 
islands (the most commonly known epigenetic 
mechanism) (23).
The aim of this study is to assess the hypoth-
esis (12) suggesting RORA silencing in autistic 
children by conducting a study on three pairs of 
discordant MZ twins for autism using microarray 
screening method and MSP confirmation. It should 
be noted that Nguyen et al. (12) also suggested a 
quantitative relationship between the severity of 
autistic phenotype and RORA gene expression. 
They also suggested that the expression level of 
RORA is regulated by DNA methylation on its 
promoter. However, our study did not confirm the 
above findings about the increased methylation 
of RORA promoter regions or the consequent de-
creased gene expression.
Moreover, subsequent immunohistochemistry 
experiments showed a decreased protein level of 
this gene in the nervous tissue of post-mortem 
samples. They attributed the mRNA expression 
of RORA to its methylation because when global 
methylation was inhibited by 5-Aza-2- deoxycy-
tidine, the quantity of the mRNA transcription of 
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RORA was increased by 1.8-fold only in the lym-
phocyte cells of autistic cases, but this did not hap-
pen either in their normal siblings or in normal 
twins. This implies that the decreased RORA ex-
pression may be attributable to the level of pro-
moter methylation rather than any type of genetic 
mutation (12).
The RORα as a nuclear receptor contributing to 
the transcription of a wide range of genes in hu-
mans. It therefore has a great potential in describ-
ing defective activities of brain in autistic children. 
Activities like circadian regulation by activating 
BMAL1 (24), protecting brain against oxidative 
stress and inflammation (25), survival and differ-
entiation of Purkinje cells (26, 27) and cerebellar 
development (14) experience malfunction dur-
ing autism. Collectively, RORA may be seen as a 
candidate gene for autism sensitivity. Moreover, 
RORA may shed light on an old question relat-
ing to an important hypothesis in autism, i.e. in-
creased testosterone levels in the amniotic fluid 
of autistic children, reported about a decade ago 
(28). Sarachana et al. (29) agreed that, as a tran-
scription factor, RORα can increase the aromatase 
enzyme level in the nervous system. This enzyme 
converts testosterone to estrogen in the nervous 
system. In fact, aromatase expression decrease as 
RORA expression decrease which, in turn, results 
in testosterone level increase in amniotic fluid and 
embryonic brain.
Nevertheless, without ignoring the probable role 
of epigenome in the molecular pathogenesis of au-
tism, our study could not confirm this association 
in autistic children of Isfahan. Surprisingly, Wong 
et al. (30) analyzed the methylome of 50 discord-
ant autistic twins and although they identified a 
considerable number of methylated genes, RORA 
showed no significant difference between autistic 
and normal children.
The following reasons may clarify this inconsist-
ency. The first is that the promoter methylation of 
RORA and the consequent decreased mRNA ex-
pression in the nervous tissues may not occur in 
lymphocyte cells. It is accepted that DNA meth-
ylation can differ cell by cell. On this basis, this 
methylation mosaicism can be expected in dif-
ferent tissues, especially in the event of hyper-
methylation (like RORA promoter methylation), 
during cell growth and differentiation. However, 
there is no detailed information about its prob-
able mechanisms. The second reason pertains to 
the technical differences of the studies. Although 
MSP is a simple, fast method for screening pro-
moter methylation, it is, however, limited to test-
ing the methylation status in just one CpG site. 
Therefore, compared with MCA-Meth, it shows a 
weak performance in detecting the methylation of 
a genomic region. Our study considered 13 CpG 
sites in the promoter region of RORA and con-
firmed no DNA methylation in the target sites. 
Some studies have compared the capability of 
MSP and MCA-Meth in detecting a methylated 
region and reported that MCA-Meth has a higher 
capability (21). Therefore, it can be argued that 
although both techniques are valuable, they may 
report different results for the methylation of a 
target region.
The third possibility is that the methylation re-
ported by Nguyen et al. (12) in the American pop-
ulation may be associated with an environmental 
factor not experienced by the population studied 
here. In other words, since the tissue mosaicism of 
DNA methylation is an accepted phenomenon, it is 
probable that this epimutation has an environmen-
tal clue in different populations.
The results of our study may disagree with those 
of Nguyen et al. (12) study from a genomic point 
of view because it has not yet been discovered 
which CpG site in the RORA promoter accom-
panies the gene silencing. It is therefore prob-
able that the methylation of an CpG nucleotide 
outside of the considered region (but inside the 
RORA promoter region) may be associated with 
its decreased expression. For example, a number 
of studies on TIMP3 gene have emphasized that 
only one region of the three overlapping regions 
of the TIMP3 promoter CpG island has a rela-
tionship with its silencing. On this basis, it can be 
argued that, at least in some genes, the methyla-
tion of specific CpG sites in the CpG island plays 
a greater role in gene silencing than other sites. 
Therefore, the RORA promoter CpG island may 
follow such epigenetic pattern. 
Conclusion
Nevertheless the methylation of RORα promoter 
region may not be considered as a common epi-
genetic risk factor for autism in all populations. 
Hence, the molecular pathogenesis of autism re-
mains unclear in the population investigated. 
 CELL JOURNAL(Yakhteh), Vol 18, No 4, Jan-Mar (winter) 2017 546
RORA and Autism
Acknowledgments
This work was financially supported by the 
Behavioral Sciences Research Center. Hereby, 
we are very thankful to Dr. Mohsen Karimi, 
Dr. Esmat Kamali, the Rehabilitation Center of 
Isfahan Welfare Organization and the Isfahan 
Society for Autistic Children for their generous 
support. The authors declare that they have no 
competing interests.
References
1. Schanen NC. Epigenetics of autism spectrum disorders. 
Hum Mol Genet. 2006; 15 Spec No 2: R138-150.
2. Pardo CA, Eberhart CG. The neurobiology of autism. 
Brain Pathol. 2007; 17(4): 434-447. 
3. Fombonne E. Epidemiology of pervasive developmental 
disorders. Pediatr Res. 2009; 65(6): 591-598. 
4. Burmeister M, McInnis MG, Zöllner S. Psychiatric genet-
ics: progress amid controversy. Nat Rev Genet. 2008; 
9(7): 527-540.
5. Iwata K, Matsuzaki H, Takei N, Manabe T, Mori N. Animal 
models of autism: an epigenetic and environmental view-
point. J Cent Nerv Syst Dis. 2010; 2: 37-44.  
6. Loat CS, Curran S, Lewis CM, Duvall J, Geschwind D, 
Bolton P, et al. Methyl-CpG-binding protein 2 polymor-
phisms and vulnerability to autism. Genes Brain Behav. 
2008; 7(7): 754-760. 
7. Gregory SG, Connelly JJ, Towers AJ, Johnson J, Bis-
cocho D, Markunas CA, et al. Genomic and epigenetic 
evidence for oxytocin receptor deficiency in autism. BMC 
Med. 2009; 7: 62.
8. Ladd-Acosta C, Hansen KD, Briem E, Fallin MD, Kauf-
mann WE, Feinberg AP. Common DNA methylation alter-
ations in multiple brain regions in autism. Mol Psychiatry. 
2013; 19(8): 862-871. 
9. Hu VW, Sarachana T, Kim KS, Nguyen A, Kulkarni S, 
Steinberg ME, et al. Gene expression profiling differen-
tiates autism case–controls and phenotypic variants of 
autism spectrum disorders: evidence for circadian rhythm 
dysfunction in severe autism. Autism Res. 2009; 2(2): 78-
97. 
10. Nakagawa Y, O’Leary DD. Dynamic patterned expression 
of orphan nuclear receptor genes RORα and RORβ in de-
veloping mouse forebrain. Dev Neurosci. 2003; 25(2-4): 
234-244. 
11. Jetten AM. Retinoid-related orphan receptors (RORs): 
critical roles in development, immunity, circadian rhythm, 
and cellular metabolism. Nucl Recept Signal. 2009; 7: 
e003. 
12. Nguyen A, Rauch TA, Pfeifer GP, Hu VW. Global meth-
ylation profiling of lymphoblastoid cell lines reveals epi-
genetic contributions to autism spectrum disorders and 
a novel autism candidate gene, RORA, whose protein 
product is reduced in autistic brain. FASEB J. 2010; 24(8): 
3036-3051. 
13. Meyer T, Kneissel M, Mariani J, Fournier B. In vitro and in 
vivo evidence for orphan nuclear receptor RORα function 
in bone metabolism. Proc Natl Acad Sci. 2000; 97(16): 
9197-9202.
14. Gold DA, Gent PM, Hamilton BA. RORα in genetic control 
of cerebellum development: 50 staggering years. Brain 
Res. 2007; 1140: 19-25. 
15. Serra HG, Duvick L, Zu T, Carlson, K Stevens S, Jor-
gensen N, et al. Roralpha-mediated purkinje cell develop-
ment determines disease severity in adult sca1 mice. Cell. 
2006; 127(4): 697-708. 
16. Li LC, Dahiya R. MethPrimer: designing primers for meth-
ylation PCRs. Bioinformatics. 2002; 18(11): 1427-1431.
17. Raichur S, Fitzsimmons RL, Myers SA, Pearen MA, Lau 
P, Eriksson N, et al. Identification and validation of the 
pathways and functions regulated by the orphan nuclear 
receptor, ROR alpha1, in skeletal muscle. Nucleic Acids 
Res. 2010; 38(13): 4296-4312. 
18. Esmaeili A, Zaker SR. Differential expression of glycine 
receptor subunit messenger RNA in the rat following spi-
nal cord injury. Spinal Cord. 2011; 49(2): 280-284. 
19. Wittwer CT, Reed GH, Gundry CN, Vandersteen JG, Pryor 
RJ. High-resolution genotyping by amplicon melting anal-
ysis using LCGreen. Clin Chem. 2003; 49(6): 853-860.   
20. Smith E, Jones ME, Drew PA. Quantitation of DNA meth-
ylation by melt curve analysis. BMC Cancer. 2009; 9: 123. 
21. Lorente A, Mueller W, Urdangarín E, Lázcoz P, Von Deim-
ling A, Castresana JS. Detection of methylation in promot-
er sequences by melting curve analysis-based semiquan-
titative real time PCR. BMC Cancer. 2008; 8: 61.  
22. Deaton AM, Bird A. CpG islands and the regulation of tran-
scription. Genes Dev. 2011; 25(10): 1010-1022. 
23. Bollati V, Baccarelli A. Environmental epigenetics. Hered-
ity. 2010; 105(1): 105-112. 
24. Akashi M, Takumi T. The orphan nuclear receptor RORα 
regulates circadian transcription of the mammalian core-
clock Bmal1. Nat Struct Mol Biol. 2005; 12(5): 441-448. 
25. Boukhtouche F, Vodjdani G, Jarvis CI, Bakouche J, Staels 
B, Mallet J, et al. Human retinoic acid receptor-related 
orphan receptor α1 overexpression protects neurones 
against oxidative stress-induced apoptosis. J Neurochem. 
2006; 96(6): 1778-1789.  
26. Boukhtouche F, Doulazmi M, Frederic F, Dusart I, Brugg 
B, Mariani J.  RORalopha, a pivotal nuclear receptor for 
Purkinje neuron survival and differentiation: from develop-
ment to ageing. Cerebellum. 2006; 5(2): 97-104.   
27. Harding HP, Atkins GB, Jaffe AB, Seo WJ, Lazar MA. 
Transcriptional activation and repression by RORalpha, 
an orphan nuclear receptor required for cerebellar devel-
opment. Mol Endocrinol. 1997; 11(11): 1737-1746. 
28. Baron-Cohen S. The extreme male brain theory of autism. 
Trends Cogn Sci. 2002; 6(6): 248-254. 
29. Sarachana T, Xu M, Wu RC, Hu VW. Sex hormones in 
autism: androgens and estrogens differentially and recip-
rocally regulate RORA, a novel candidate gene for autism. 
PLoS One. 2011; 6(2):  e17116. 
30. Wong CC, Meaburn EL, Ronald A, Price TS, Jeffries AR, 
Schalkwyk LC, et al. Methylomic analysis of monozygotic 
twins discordant for autism spectrum disorder and related 
behavioural traits. Mol Psychiatry. 2013; 19(4): 495-503. 
